Clinical Trials
2 trialsNCT01082315 2014-08-29
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Completed
NCT01074333 2014-06-17
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Terminated